ERBB2 and ovarian cancer: In breast cancer patients, however, fascin immunoreactivity was more prevalent in nondiploid and highly proliferating tumours with a negative hormone receptor status and Her2/neu overexpression (Sun et al, 1997; Grothey et al, 2000a,b), while in ovarian cancer it was correlated with advanced disease stage (Hu et al, 2000).